In Q2 2025, Zymeworks delivered $48,726,000 in revenue, reflecting a significant increase from the prior year, with net income of $2,317,000 and diluted EPS of $0.03, supported by milestone payments and royalty revenue from collaborations while maintaining strong cash resources of $333,400,000 at quarter end. :contentReference[oaicite:0]{index=0}
Total revenue of $48,726,000 in Q2 2025, up sharply from Q2 2024. :contentReference[oaicite:1]{index=1}
Net income of $2,317,000, reversing a net loss from the prior year. :contentReference[oaicite:2]{index=2}
Diluted EPS of $0.03 indicating profitability for the quarter. :contentReference[oaicite:3]{index=3}
Cash resources of $333,400,000 provide runway into the second half of 2027. :contentReference[oaicite:4]{index=4}
Zymeworks reaffirmed its strategic focus on advancing key clinical programs and partnerships while expecting additional milestone and royalty opportunities from ongoing collaborations.
Analyze how earnings announcements historically affect stock price performance